| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,509,396 | 26 | 100 |
| Fenton Mary Kay | Chief Financial Officer | 0 | $0 | 1 | $59,901 | $-59,901 |
| SUMER JACQUELYN L | Chief Legal Officer | 0 | $0 | 3 | $136,724 | $-136,724 |
| Jones Jeffrey Alan | Chief Medical Officer | 0 | $0 | 3 | $178,948 | $-178,948 |
| AHMED NADIM | President and CEO | 0 | $0 | 3 | $517,990 | $-517,990 |
| Michaelson Jennifer | Chief Scientific Officer | 0 | $0 | 16 | $1.62M | $-1.62M |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or …
Over the last 12 months, insiders at Cullinan Therapeutics, Inc. have bought $0 and sold $2.51M worth of Cullinan Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cullinan Therapeutics, Inc. have bought $9.07M and sold $1.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 165,667 shares for transaction amount of $1.39M was made by Lynx1 Capital Management LP (10 percent owner) on 2025‑10‑28.
| 2026-09-08 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0129% | $21.57 | $172,560 | -28.79% | |
| 2026-08-13 | Sale | Michaelson Jennifer | Chief Scientific Officer | 30,000 0.0504% | $20.26 | $607,800 | -17.26% | |
| 2026-07-06 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.013% | $17.82 | $142,560 | -0.90% | |
| 2026-05-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0127% | $14.62 | $116,996 | +11.68% | |
| 2026-03-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0136% | $15.68 | $125,440 | -0.99% | |
| 2026-02-25 | Sale | Michaelson Jennifer | Chief Scientific Officer | 1,780 0.003% | $14.14 | $25,169 | +7.66% | |
| 2026-02-24 | Sale | AHMED NADIM | President and CEO | 13,515 0.0232% | $14.47 | $195,562 | +8.34% | |
| 2026-02-24 | Sale | Michaelson Jennifer | Chief Scientific Officer | 3,601 0.0062% | $14.47 | $52,106 | +8.34% | |
| 2026-02-24 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,582 0.0079% | $14.47 | $66,302 | +8.34% | |
| 2026-02-24 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,601 0.0062% | $14.47 | $52,106 | +8.34% | |
| 2026-02-23 | Sale | Michaelson Jennifer | Chief Scientific Officer | 1,752 0.003% | $13.99 | $24,510 | +10.47% | |
| 2026-02-20 | Sale | AHMED NADIM | President and CEO | 16,381 0.0277% | $13.62 | $223,109 | +13.19% | |
| 2026-02-20 | Sale | Michaelson Jennifer | Chief Scientific Officer | 11,742 0.0205% | $14.08 | $165,366 | +13.19% | |
| 2026-02-20 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,982 0.0084% | $13.62 | $67,855 | +13.19% | |
| 2026-02-20 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,742 0.0063% | $13.62 | $50,966 | +13.19% | |
| 2026-02-20 | Sale | Fenton Mary Kay | Chief Financial Officer | 4,398 0.0074% | $13.62 | $59,901 | +13.19% | |
| 2026-02-12 | Sale | Michaelson Jennifer | Chief Scientific Officer | 416 0.0007% | $12.03 | $5,004 | +31.35% | |
| 2026-01-22 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,000 0.0066% | $12.30 | $49,200 | +21.00% | |
| 2025-12-23 | Sale | AHMED NADIM | President and CEO | 9,922 0.0163% | $10.01 | $99,319 | +49.35% | |
| 2025-12-19 | Sale | Michaelson Jennifer | Chief Scientific Officer | 1,345 0.0024% | $10.01 | $13,463 | +54.18% |
| AHMED NADIM | President and CEO | 390803 0.6359% | $6.16M | 1 | 10 | <0.0001% |
| Lynx1 Capital Management LP | 10 percent owner | 8963500 14.5847% | $141.18M | 8 | 0 | +88.54% |
| UBS Oncology Impact Fund L.P. | 10 percent owner | 7648268 12.4447% | $120.46M | 1 | 18 | <0.0001% |
| LAMPERT MARK N | 4058854 6.6043% | $63.93M | 3 | 0 | +15.29% | |
| Jovan-Embiricos Morana | 1281952 2.0859% | $20.19M | 1 | 3 | <0.0001% | |
| Hughes Owen | President and CEO | 506226 0.8237% | $7.97M | 1 | 0 | <0.0001% |
| GADICKE ANSBERT | 244551 0.3979% | $3.85M | 1 | 18 | <0.0001% | |
| Trigilio Jeffrey | Chief Financial Officer | 83919 0.1365% | $1.32M | 1 | 12 | <0.0001% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 96 | +67.13% | 13M | +21.87% |
| Decreased Positions | 63 | -44.06% | 11M | -18.12% |
| New Positions | 31 | New | 4M | New |
| Sold Out Positions | 20 | Sold Out | 3M | Sold Out |
| Total Postitions | 176 | +23.08% | 63M | +3.76% |
| Mpm Bioimpact Llc | $77,400.00 | 12.96% | 7.65M | 0 | 0% | 2025-09-30 |
| Lynx1 Capital Management Lp | $58,353.00 | 9.77% | 5.77M | +1M | +31.02% | 2025-09-30 |
| Bvf Inc/Il | $58,197.00 | 9.75% | 5.75M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $42,200.00 | 7.07% | 4.17M | -47,971 | -1.14% | 2025-09-30 |
| Vanguard Group Inc | $29,786.00 | 4.99% | 2.94M | -76,775 | -2.54% | 2025-09-30 |
| Deerfield Management Company, L.P. | $29,621.00 | 4.96% | 2.93M | -928,539 | -24.08% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $25,411.00 | 4.26% | 2.51M | +125,000 | +5.24% | 2025-09-30 |
| Kynam Capital Management, Lp | $23,298.00 | 3.9% | 2.3M | +206,174 | +9.84% | 2025-09-30 |
| Citadel Advisors Llc | $20,082.00 | 3.36% | 1.98M | -629,286 | -24.08% | 2025-09-30 |
| Orbimed Advisors Llc | $19,469.00 | 3.26% | 1.92M | 0 | 0% | 2025-09-30 |